Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for edaravone dextroxol concentrated solution (specification: 5ml: edaravone 10 mg and dexcamol 2.5 mg) was accepted. This drug is suitable for improving neurological symptoms, daily living ability, and dysfunction caused by acute ischemic stroke.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.